T-Curx won Swissmedic approval for a first-in-human phase I study of TCX-001, a Siglec-6-targeted nonviral CAR T program. The trial will enroll adults with relapsed or refractory AML and CLL, including patients not eligible for stem cell transplantation, with initial study sites in Switzerland and an EMA submission planned to expand to Germany. On diagnostic strategy for oncology, researchers reported that an ultra-sensitive HPV sequencing liquid biopsy approach can detect minimal residual disease early in HPV-positive head and neck cancer. In the prospective Clear-HPVca observational trial, the HPV-DeepSeek workflow identified more MRD cases than conventional droplet digital PCR, supporting the approach for earlier recurrence detection and postoperative risk stratification.